Compare Harmony Gold Mining Co. (HMY) vs Pfizer Inc (PFE) Price & Performance

Harmony Gold Mining (HMY) trades at $19.90, up 0.96% with strong technical momentum as moving averages signal bullish alignment. The company demonstrates robust fundamentals with 2024 revenue of $61.38B and net income of $8.59B, achieving a 20.06% net margin. Recent earnings show mixed results with a Q4 2025 miss but strong operational cash flow growth to $15.65B in 2024. The stock's valuation remains reasonable with P/E of 12.26 and EV/EBITDA of 6.41, while the company transitions toward gold-copper diversification.

HMY presents a compelling value proposition with attractive profitability metrics and strategic diversification, though analyst sentiment remains cautious with 70% hold ratings. Key risks include gold price volatility and execution challenges in copper expansion. The stock trades near resistance at $20-21 with overbought RSI signals suggesting potential near-term consolidation before further upside.

Pfizer (PFE) trades at $27.05, up 1.16% with a bullish technical signal and consistent earnings beats in recent quarters. Revenue remains stable around $62-63 billion, though net income is projected to decline in 2026. The stock shows strong profitability margins and a solid balance sheet, but faces headwinds from patent expirations and competitive pressures.

The outlook is mixed: valuation multiples appear reasonable, and analyst consensus leans hold with a $27.86 target. Key risks include execution on pipeline catalysts and margin compression. Upside depends on successful drug launches and cost management amid a challenging revenue environment.